


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

A is -NH-, -N(C₁-C₆)alkyl-, or -N-(O-C₁-C₆ alkyl)-;

R₁ is -halo, -CH₃, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each R₂ is independently:

(a) -halo, -OH, or -NH₂;

(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl,

each of which is unsubstituted or substituted with one or more R₆ groups;

each R₃ is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;

(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

R₄ is:

(a) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(b) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

each R₅ is independently -CN, -OH, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₆ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

2. (original) The compound of claim 1, wherein:


n is 0;

m is 0; and

R₄ is phenyl.

3. (original) The compound of claim 2, wherein the R₄ phenyl is unsubstituted.
4. (original) The compound of claim 2, wherein the R₄ phenyl is substituted at the 4-position.
5. (original) The compound of claim 4, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.
6. (original) The compound of claim 5, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.
7. (original) The compound of claim 5, wherein the -(C₁-C₆) alkyl group is an *iso*-propyl group.
8. (original) The compound of claim 4, wherein the R₄ phenyl is substituted with a -CF₃ group.
9. (original) The compound of claim 4, wherein the R₄ phenyl is substituted with a -OCF₃ group.
10. (original) The compound of claim 1, wherein:
 - n is 0;
 - m is 1;
 - R₃ is methyl; and
 - R₄ is phenyl.
11. (original) The compound of claim 10, wherein the R₄ phenyl is unsubstituted.
12. (original) The compound of claim 10, wherein the R₄ phenyl is substituted at the 4-position.
13. (original) The compound of claim 12, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.

14. (original) The compound of claim 13, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.
15. (original) The compound of claim 13, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.
16. (currently amended) The compound of claim 12, wherein the \underline{R}_4 phenyl is substituted with a $-CF_3$ group.
17. (currently amended) The compound of claim 12, wherein the \underline{R}_4 phenyl is substituted with a $-OCF_3$ group.
18. (original) The compound of claim 1, wherein A is $-NH-$.
19. (original) The compound of claim 1, wherein A is $-N(C_1-C_6)alkyl-$.
20. (original) The compound of claim 1, wherein A is $-N-(O-C_1-C_6 alkyl)-$.
21. (currently amended) A compound of formula (II):



(II)

or a pharmaceutically acceptable salt thereof, wherein:

A is $-N(O-C_1-C_6 alkyl)-$, $-CH_2-$, $-CH_2CH_2-$, or $-CH=CH-$;

R_1 is $-halo$, $-CH_3$, $-NO_2$, $-CN$, $-OH$, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, or $-CH_2(halo)$;

each R_2 is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;
 (b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

each R₃ is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;
 (b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

R₄ is:

(a) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(b) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

each R₅ is independently -CN, -OH, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₆ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂ or -CH₂(halo);

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.


22. (original) The compound of claim 21, wherein:
n is 0;
m is 0; and
R₄ is phenyl.
23. (original) The compound of claim 22, wherein the R₄ phenyl is unsubstituted.
24. (original) The compound of claim 22, wherein the R₄ phenyl is substituted at the 4-position.
25. (original) The compound of claim 24, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.
26. (original) The compound of claim 25, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.
27. (original) The compound of claim 25, wherein the -(C₁-C₆) alkyl group is an *iso*-propyl group.
28. (original) The compound of claim 24, wherein the R₄ phenyl is substituted with a -CF₃ group.
29. (original) The compound of claim 24, wherein the R₄ phenyl is substituted with a -OCF₃ group.
30. (original) The compound of claim 21, wherein:
n is 0;
m is 1;

R₃ is methyl; and

R₄ is phenyl.

31. (original) The compound of claim 30, wherein the R₄ phenyl is unsubstituted.
32. (original) The compound of claim 30, wherein the R₄ phenyl is substituted at the 4-position.
33. (original) The compound of claim 32, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.
34. (original) The compound of claim 33, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.
35. (original) The compound of claim 33, wherein the -(C₁-C₆) alkyl group is an *iso*-propyl group.
36. (original) The compound of claim 32, wherein the R₄ phenyl is substituted with a -CF₃ group.
37. (original) The compound of claim 32, wherein the R₄ phenyl is substituted with a -OCF₃ group.
38. (original) The compound of claim 21, wherein A is -N(O-C₁-C₆ alkyl)-.
39. (original) The compound of claim 21, wherein A is -CH₂-.
40. (original) The compound of claim 21, wherein A is -CH₂CH₂-.
41. (original) The compound of claim 21, wherein A is -CH=CH-.

42. (currently amended) A compound of formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:

A is -NH- or ~~-N(C₁-C₆alkyl)-~~ -N(C₁-C₆)alkyl-;

R_1 is -halo, -CH₃, -NO₂, -CN, -OH, -OCH₃, -NH₂, -C(halo)_3 , -CH(halo)₂, or -CH₂(halo);

each R_2 is independently:

(a) -halo, -OH, or -NH₂;

(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

each R_3 is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;

(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R_5 groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R_6 groups;

R₄ is:

(a) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(b) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

each R₅ is independently -CN, -OH, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₆ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2; and

m is an integer ranging from 0 to 2.

43. (original) The compound of claim 42, wherein:

n is 0;

m is 0; and

R₄ is phenyl.

44. (original) The compound of claim 43, wherein the R₄ phenyl is unsubstituted.

45. (original) The compound of claim 43, wherein the R₄ phenyl is substituted at the 4-position.

46. (original) The compound of claim 45, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.

47. (original) The compound of claim 46, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.

48. (original) The compound of claim 46, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

49. (original) The compound of claim 45, wherein the R_4 phenyl is substituted with a $-CF_3$ group.

50. (original) The compound of claim 45, wherein the R_4 phenyl is substituted with a $-OCF_3$ group.

51. (original) The compound of claim 42, wherein:

n is 0;

m is 1;

R_3 is methyl; and

R_4 is phenyl.

52. (original) The compound of claim 51, wherein the R_4 phenyl is unsubstituted.

53. (original) The compound of claim 51, wherein the R_4 phenyl is substituted at the 4-position.

54. (original) The compound of claim 53, wherein the R_4 phenyl is substituted with a $-(C_1-C_6)$ alkyl group.

55. (original) The compound of claim 54, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.

56. (original) The compound of claim 54, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

57. (original) The compound of claim 53, wherein the R_4 phenyl is substituted with a $-CF_3$ group.

58. (original) The compound of claim 53, wherein the R₄ phenyl is substituted with a -OCF₃ group.

59. (original) The compound of claim 42, wherein A is -NH-.

60. (currently amended) The compound of claim 42, wherein A is ~~N(C₁-C₆ alkyl)~~ -N(C₁-C₆)alkyl-.

61. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

62. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

63. (original) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42 and a pharmaceutically acceptable carrier or excipient.

64. (original) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

65. (original) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

66. (original) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

67. (original) A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

68. (original) A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

69. (original) A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

70. (original) A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

71. (original) A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

72. (original) A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

73. (original) A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

74. (original) A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

75. (original) A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

76. (original) A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

77. (original) A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

78. (original) A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

79. (original) A method for inhibiting VR1 function in a cell comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1.

80. (original) A method for inhibiting VR1 function in a cell comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 21.

81. (original) A method for inhibiting VR1 function in a cell comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 42.

82. (original) A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 1.

83. (original) A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 21.


84. (original) A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim 42.

85. (original) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

86. (original) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 21 and a pharmaceutically acceptable carrier or excipient.

87. (original) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim 42 and a pharmaceutically acceptable carrier or excipient.


88. (currently amended) A compound of formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein:

Ar₂ is



R₁ is -H, -halo, -CH₃, -NO₂, -CN, -OH, -OCH₃, -NH₂, $\text{-}\overset{\text{O}}{\underset{\text{O}}{\text{C}}}(\text{halo})_3$, -CH(halo)₂, or -CH₂(halo);

each R₂ is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;

(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl,

each of which is unsubstituted or substituted with one or more R₆ groups;

each R₃ is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;

(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

each R₅ is independently -CN, -OH, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₆ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each R₈ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each R₉ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -C(halo)₃, -CH(halo)₂, ~~or~~ -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₁₁ is independently -CN, -OH, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2;

m is 0 or 1;

o is an integer ranging from 0 to 4;

q is an integer ranging from 0 to 6;

r is an integer ranging from 0 to 5;

s is an integer ranging from 0 to 4; and

t is an integer ranging from 0 to 2.

89. (currently amended) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88 and a pharmaceutically acceptable carrier or excipient.

90. (currently amended) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

91. (currently amended) A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

92. (currently amended) A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

93. (currently amended) A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

94. (currently amended) A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

95. (currently amended) A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.


96. (currently amended) A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88.

97. Canceled

98. Canceled

99. (currently amended) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim ~~87~~ 88 and a pharmaceutically acceptable carrier or excipient.


100. (currently amended) A compound of formula (V):



(V)

or a pharmaceutically acceptable salt thereof, wherein:

Ar_2 is



R_1 is -H, -halo, -CH₃, -NO₂, -CN, -OH, -OCH₃, -NH₂, $-C(halo)_3$, -CH(halo)₂, or -CH₂(halo);

each R_2 is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;

(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

each R₃ is independently:

(a) -halo, -CN, -OH, -NO₂, or -NH₂;

(b) -(C₁-C₁₀)alkyl, -(C₂-C₁₀)alkenyl, -(C₂-C₁₀)alkynyl, -(C₃-C₁₀)cycloalkyl, -(C₈-C₁₄)bicycloalkyl, -(C₈-C₁₄)tricycloalkyl, -(C₅-C₁₀)cycloalkenyl, -(C₈-C₁₄)bicycloalkenyl, -(C₈-C₁₄)tricycloalkenyl, -(3- to 7-membered)heterocycle, or -(7- to 10-membered)bicycloheterocycle, each of which is unsubstituted or substituted with one or more R₅ groups; or

(c) -phenyl, -naphthyl, -(C₁₄)aryl or -(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with one or more R₆ groups;

each R₅ is independently -CN, -OH, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₆ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₇ is independently -H, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each R₈ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -(3- to 5-membered)heterocycle, -C(halo)₃, -CH(halo)₂, or -CH₂(halo);

each R₉ is independently -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -(C₃-C₈)cycloalkyl, -(C₅-C₈)cycloalkenyl, -phenyl, -C(halo)₃, -CH(halo)₂, or -CH₂(halo), -CN, -OH, -halo, -N₃, -NO₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each R₁₁ is independently -CN, -OH, -(C₁-C₆)alkyl, -(C₂-C₆)alkenyl, -(C₂-C₆)alkynyl, -halo, -N₃, -NO₂, -N(R₇)₂, -CH=NR₇, -NR₇OH, -OR₇, -COR₇, -C(O)OR₇, -OC(O)R₇, -OC(O)OR₇, -SR₇, -S(O)R₇, or -S(O)₂R₇;

each halo is independently -F, -Cl, -Br, or -I;

n is an integer ranging from 0 to 2;

m is 0 or 1;

o is an integer ranging from 0 to 4;

q is an integer ranging from 0 to 6;

r is an integer ranging from 0 to 5;

s is an integer ranging from 0 to 4; and

t is an integer ranging from 0 to 2.

101. (currently amended) A composition comprising an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100 and a pharmaceutically acceptable carrier or excipient.

102. (currently amended) A method for treating pain in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

103. (currently amended) A method for treating urinary incontinence in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

104. (currently amended) A method for treating an ulcer in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

105. (currently amended) A method for treating irritable-bowel syndrome in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

106. (currently amended) A method for treating inflammatory-bowel disease in an animal, comprising administering to an animal in need thereof an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

107. (currently amended) A method for inhibiting VR1 function in a cell, comprising contacting a cell capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

108. (currently amended) A kit comprising a container containing an effective amount of a compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100.

109. Canceled

110. Canceled

111. (currently amended) A method for preparing a composition, comprising the step of admixing a compound or a pharmaceutically acceptable salt of the compound of claim ~~99~~ 100 and a pharmaceutically acceptable carrier or excipient.

112. (original) The compound of claim 1, wherein:

n is 0;

m is 1;

R₃ is -CH₃;

R₁ is -halo; and

R₄ is phenyl.

113. (original) The compound of claim 112, wherein the R₄ phenyl is unsubstituted.

114. (original) The compound of claim 112, wherein the R₄ phenyl is substituted at the 4-position.

115. (original) The compound of claim 114, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.

116. (original) The compound of claim 115, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.

117. (original) The compound of claim 115, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

118. (currently amended) The compound of claim 114, wherein the R_4 phenyl is substituted with a $-CF_3$ group.

119. (currently amended) The compound of claim 114, wherein the R_4 phenyl is substituted with a $-OCF_3$ group.

120. (original) The compound of claim 112, wherein R_1 is $-Cl$.

121. (original) The compound of claim 120, wherein the R_4 phenyl is unsubstituted.

122. (original) The compound of claim 120, wherein the R_4 phenyl is substituted at the 4-position.

123. (original) The compound of claim 122, wherein the R_4 phenyl is substituted with a $-(C_1-C_6)$ alkyl group.

124. (original) The compound of claim 123, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.

125. (original) The compound of claim 123, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

126. (currently amended) The compound of claim 122, wherein the R_4 phenyl is substituted with a $-CF_3$ group.

127. (currently amended) The compound of claim 122, wherein the R_4 phenyl is substituted with a $-OCF_3$ group.

128. (original) The compound of claim 112, wherein R₁ is -F.
129. (original) The compound of claim 128, wherein the R₄ phenyl is unsubstituted.
130. (original) The compound of claim 128, wherein the R₄ phenyl is substituted at the 4-position.
131. (original) The compound of claim 130, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.
132. (original) The compound of claim 131, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.
133. (original) The compound of claim 131, wherein the -(C₁-C₆) alkyl group is an *iso*-propyl group.
134. (currently amended) The compound of claim 130, wherein the R₄ phenyl is substituted with a -CF₃ group.
135. (currently amended) The compound of claim 130, wherein the R₄ phenyl is substituted with a -OCF₃ group.
136. (original) The compound of claim 1, wherein:
n is 0;
m is 1;
R₃ is -CH₃;
R₁ is -CH₃; and
R₄ is phenyl.
137. (original) The compound of claim 136, wherein the R₄ phenyl is unsubstituted.
138. (original) The compound of claim 136, wherein the R₄ phenyl is substituted at the 4-position.

139. (original) The compound of claim 138, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.

140. (original) The compound of claim 139, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.

141. (original) The compound of claim 139, wherein the -(C₁-C₆) alkyl group is an *iso*-propyl group.

142. (currently amended) The compound of claim 138, wherein the R₄ phenyl is substituted with a -CF₃ group.

143. (currently amended) The compound of claim 138, wherein the R₄ phenyl is substituted with a -OCF₃ group.

144. (original) The compound of claim 21, wherein:

n is 0;

m is 1;

R₃ is -CH₃;

R₁ is -halo; and

R₄ is phenyl.

145. (original) The compound of claim 144, wherein the R₄ phenyl is unsubstituted.

146. (original) The compound of claim 144, wherein the R₄ phenyl is substituted at the 4-position.

147. (original) The compound of claim 146, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.

148. (original) The compound of claim 147, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.

149. (original) The compound of claim 147, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

150. (currently amended) The compound of claim 146, wherein the R_4 phenyl is substituted with a $-CF_3$ group.

151. (currently amended) The compound of claim 146, wherein the R_4 phenyl is substituted with a $-OCF_3$ group.

152. (original) The compound of claim 144, wherein R_1 is $-Cl$.

153. (original) The compound of claim 152, wherein the R_4 phenyl is unsubstituted.

154. (original) The compound of claim 152, wherein the R_4 phenyl is substituted at the 4-position.

155. (original) The compound of claim 154, wherein the R_4 phenyl is substituted with a $-(C_1-C_6)$ alkyl group.

156. (original) The compound of claim 155, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.

157. (original) The compound of claim 155, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

158. (currently amended) The compound of claim 154, wherein the R_4 phenyl is substituted with a $-CF_3$ group.

159. (currently amended) The compound of claim 154, wherein the R_4 phenyl is substituted with a $-OCF_3$ group.

160. (original) The compound of claim 144, wherein R_1 is $-F$.

161. (original) The compound of claim 160, wherein the R₄ phenyl is unsubstituted.

162. (original) The compound of claim 160, wherein the R₄ phenyl is substituted at the 4-position.

163. (original) The compound of claim 162, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.

164. (original) The compound of claim 163, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.

165. (original) The compound of claim 163, wherein the -(C₁-C₆) alkyl group is an *iso*-propyl group.

166. (currently amended) The compound of claim 162, wherein the R₄ phenyl is substituted with a -CF₃ group.

167. (currently amended) The compound of claim 162, wherein the R₄ phenyl is substituted with a -OCF₃ group.

168. (original) The compound of claim 21, wherein:
n is 0;
m is 1;
R₁ is -CH₃; and
R₄ is phenyl.

169. (original) The compound of claim 168, wherein the R₄ phenyl is unsubstituted.

170. (original) The compound of claim 168, wherein the R₄ phenyl is substituted at the 4-position.

171. (original) The compound of claim 170, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.

172. (original) The compound of claim 171, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.

173. (original) The compound of claim 171, wherein the -(C₁-C₆) alkyl group is an *iso*-propyl group.

174. (currently amended) The compound of claim 170, wherein the R₄ phenyl is substituted with a -CF₃ group.

175. (currently amended) The compound of claim 170, wherein the R₄ phenyl is substituted with a -OCF₃ group.

176. (original) The compound of claim 42, wherein:

n is 0;

m is 1;

R₃ is -CH₃;

R₁ is -halo; and

R₄ is phenyl.

177. (original) The compound of claim 176, wherein the R₄ phenyl is unsubstituted.

178. (original) The compound of claim 176, wherein the R₄ phenyl is substituted at the 4-position.

179. (original) The compound of claim 178, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.

180. (original) The compound of claim 179, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.

181. (original) The compound of claim 179, wherein the -(C₁-C₆) alkyl group is an *iso*-propyl group.

182. (currently amended) The compound of claim 178, wherein the R₄ phenyl is substituted with a -CF₃ group.

183. (currently amended) The compound of claim 178, wherein the R₄ phenyl is substituted with a -OCF₃ group.

184. (original) The compound of claim 176, wherein R₁ is -Cl.

185. (original) The compound of claim 184, wherein the R₄ phenyl is unsubstituted.

186. (original) The compound of claim 184, wherein the R₄ phenyl is substituted at the 4-position.

187. (original) The compound of claim 186, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.

188. (original) The compound of claim 187, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.

189. (original) The compound of claim 187, wherein the -(C₁-C₆) alkyl group is an *iso*-propyl group.

190. (currently amended) The compound of claim 186, wherein the R₄ phenyl is substituted with a -CF₃ group.

191. (currently amended) The compound of claim 186, wherein the R₄ phenyl is substituted with a -OCF₃ group.

192. (original) The compound of claim 176, wherein R₁ is -F.

193. (original) The compound of claim 192, wherein the R₄ phenyl is unsubstituted.

194. (original) The compound of claim 192, wherein the R₄ phenyl is substituted at the 4-position.

195. (original) The compound of claim 194, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.

196. (original) The compound of claim 195, wherein the -(C₁-C₆) alkyl group is a *tert*-butyl group.

197. (original) The compound of claim 195, wherein the -(C₁-C₆) alkyl group is an *iso*-propyl group.

198. (currently amended) The compound of claim 194, wherein the R₄ phenyl is substituted with a -CF₃ group.

199. (currently amended) The compound of claim 194, wherein the R₄ phenyl is substituted with a -OCF₃ group.

200. (original) The compound of claim 42, wherein:

n is 0;

m is 1;

R₃ is -CH₃;

R₁ is -CH₃; and

R₄ is phenyl.

201. (original) The compound of claim 200, wherein the R₄ phenyl is unsubstituted.

202. (original) The compound of claim 200, wherein the R₄ phenyl is substituted at the 4-position.

203. (original) The compound of claim 202, wherein the R₄ phenyl is substituted with a -(C₁-C₆) alkyl group.

204. (original) The compound of claim 203, wherein the $-(C_1-C_6)$ alkyl group is a *tert*-butyl group.

205. (original) The compound of claim 203, wherein the $-(C_1-C_6)$ alkyl group is an *iso*-propyl group.

206. (currently amended) The compound of claim 202, wherein the \underline{R}_4 phenyl is substituted with a $-CF_3$ group.

207. (currently amended) The compound of claim 202, wherein the \underline{R}_4 phenyl is substituted with a $-OCF_3$ group.